Company / Cash & Equivalents
Xeris Biopharma Holdings, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$111.0M
FY2025
5-year range
$67.3M / $122.0M
FY2021-FY2025
Trend
+55.0%
vs FY2024
Sector context
#135 of 207
Health Care
What the data says
At $111M, Xeris Biopharma Holdings, Inc.'s cash & equivalents ranks #135 of 207 in the Health Care sector. Improved from $67M to $111M over the past 2 years.
Based on SEC 10-K filings.
$111M in FY2025 with a 5-year CAGR of +24.2%.
Improved from $67M to $111M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -3.1%
- 5-Year CAGR
- +24.2%
- 10-Year CAGR
- -
Sector benchmark
#135 of 207 in Health CareTop 65% of 207This company $111.0M Sector average $669.5M
▼
-83.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +24.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 55.0% year-over-year.
- Ranks #135 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $111.0M | +55.0% |
| FY2024 | $71.6M | +6.2% |
| FY2023 | $67.4M | -44.7% |
| FY2022 | $122.0M | +81.3% |
| FY2021 | $67.3M | +78.9% |
| FY2020 | $37.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026